Actavis $ACT (renamed from Watson Pharma $WPI after merger) is one of numerous companies pursuing biosimilars, in collaboration with Amgen $AMGN. Here are there recent comments from the 1q-2013 earnings call (c/o SeekingAlpha). Note that their commercialization deal with Antares Pharma $ATRS for GELNIQUE was not discussed.
While Watson Pharma WPI did not discuss their GELNIQUE line (including the oxybutynin gel product licensed from Antares Pharma) on their 3q-2012 earnings call, they did make some general business comments that are relevant to the partnership:
"We are definitely committed to a long-term brand strategy. We are committed to women's health. We're committed to urology, and we're committed to a biosimilar franchise. So we will continue to look for business development opportunities. I would expect that you'll see some from us over the next few months, as we can bring home some of the deals we're currently working on. But we have not wavered in our commitment to our brand franchise
Yes, we're continuing to focus our development efforts around women's health, and this is widespread women's health, not just contraception, but we will continue to look for opportunities of underserved needs in women's health care. And there are those areas. We're looking at new therapies. We're looking at NCEs. We're looking at new delivery devices, new delivery systems. We're looking across the board at all of the options that we have presented -- we have available to ourselves. On the urology front, we continue to be focused on that. As we think about going forward, we will continue to look for opportunities to maybe add on perhaps some additional therapeutic category. We have to be careful about how we approach that. That's a challenging effort, and we would probably need to do a substantial acquisition to get ourselves into another category, but we haven't certainly said we wouldn't do that. So we are focused on all of those categories." (transcript quote via SeekingAlpha)
2012 continues to be an eventful year for Momenta Pharma and their generic drug programs for Lovenox, Copaxone, and undisclosed biosimilars or follow-on biologics (FOBs). Continue reading below for a round up of updates from MNTA's partners and competitors in the space.
For archival purposes, see below for my notes from the March 2012 Antares Pharma (stock symbol ATRS, formerly AIS) fourth quarter and full-year 2011 earnings conference call.
Momenta will present preclinical data for M402, their heparin-based drug that has just started a phase 1/2 trial in combination with gemcitabine for pancreatic cancer. Abstract will be out May 16th.
m-Enoxaparin (generic LOVENOX):
-no mention of the MNTA-BAX follow-on biologics (FOBs) / biosimilars collaboration on the Baxter quarterly conference call
-no mention of the long lost Teva Pharma $TEVA generic lovenox program on their 1q-2012 conference call.
-no discussion of enoxaparin on Novartis $NVS (Sandoz) 1q-2012 conference call.
-Sanofi $SNY 1q-2012 conference call comments (sorry for poor transcript) from Seeking Alpha and Morningstar has not yet posted one): "On the right side of the chart Lovenox performance even more remarkable, I believe was in €400 million just during the first quarter, a growth of 12%. So it says outside the U.S. where the product more or less never has been patent protected and is undergoing direct competition from [inaudible] many years. I believe [inaudible] inside US Lovenox performed [inaudible] patients mainly but not only due to the fact that we have seen no additional entries of a generic product. But I think it’s fair to say that also we have extreme customer loyalty [inaudible] evidently helped by continued supply problems of our existing competitors."
-Watson Pharma $WPI 1q-2012 conference call excerpts:
"Could you just comment a little bit about generic LOVENOX? How's that product doing for you?"
"I think it's going all right. We're getting much better supply now. We were building up supply in the beginning. I think where the issue is, just to remind you, we only have the retail part of the business versus the non-retail. There were challenges in the beginning to only sell to the retail because many of our customers supply both retail and non-retail, including the hospitals. I think we have sorted those technical issues out pretty well, and we have steadily getting more market share. I think the prices have gone a little bit lower than we expected. We clearly see that both Sandoz and Sanofi have reacted to the market. But overall, we are quite pleased with where we are with the LOVENOX product."